Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094692 | 0.86 | POLB (0.44) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL1747940 | 0.85 | MEN1 (0.59) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL22654667 | 0.85 | PKM (0.61) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL10944872 | 0.85 | KMT2A (0.49) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL7753231 | 0.83 | KMT2A (0.47) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL609522 | 0.81 | LMNA (0.57) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL464726 | 0.81 | ALDH1A1 (0.76) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL22230068 | 0.81 | KMT2A (0.51) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL22230114 | 0.81 | ILK (0.54) | KMT2AALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL11147940 | 0.79 | CA2 (0.49) | KMT2AALDH1A1HPGDKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| WO-2025045777-A1 | INHIBITORS OF PCSK9 | DRAUPNIR BIO APS (DK) | 2025-03-06 | — | — | WO | disclosed |
| CN-119112897-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119022-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119023-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| CN-119060040-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| US-4210582-A | FIBER-REACTIVE YELLOW DYES FOR WOOL | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4204056-A | Process and intermediates for preparing fiber-reactive phthalocyanine dyes | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-05-20 | — | — | US | disclosed |
| US-4191686-A | FROM SULFONYL HALIDE SUBSTITUTED PARENT BY AMIDATION WITH AROMATIC DIAMINE, DIAZOTIZING, COUPLING TO KETO SUCCINIC ESTER, CYCLIZING, COUPLING TO REACTIVE MOIETY | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| US-4141890-A | FIBER-REACTIVE | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-RE29585-E | DYEING WOOL | CIBA-GEIGY CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-4067864-A | FOR CELLULOSE OR POLYAMIDES | CIBA-GEIGY AG (CH) | 1978-01-10 | — | — | US | disclosed |
| US-4039523-A | YELLOW | CIBA-GEIGY AG (CH) | 1977-08-02 | — | — | US | disclosed |
| US-4017477-A | 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs | CIBA-GEIGY AG (CH) | 1977-04-12 | — | — | US | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-3971738-A | Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | KMT2A 3366/4885ALDH1A1 4688/4885HPGD 3206/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | KMT2A 569/4885ALDH1A1 4830/4885HPGD 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.